BPC-157
GH Secretagogues vs. Exogenous HGH: Key Differences
How CJC-1295/Ipamorelin differs from exogenous HGH (somatropin), why pulsatility matters, what a secretagogue cannot do that exogenous GH can, and the regulatory status difference between the two.
Informational only. Not medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any protocol.
The key distinction: endogenous vs. exogenous
GH secretagogues like CJC-1295/Ipamorelin and exogenous HGH (human growth hormone injections) are often discussed together, but they operate through fundamentally different mechanisms with different implications for safety, regulation, and effect.
Exogenous HGH (synthetic recombinant human growth hormone, also called somatropin) directly supplies GH from outside the body. The pituitary gland's role is bypassed — you are injecting the hormone itself.
GH secretagogues (CJC-1295, Ipamorelin, and similar compounds) stimulate the pituitary to produce and release more of the body's own GH. No GH is introduced exogenously — the drug signals the pituitary to increase secretion.
Why pulsatility matters
Natural GH secretion is pulsatile — the pituitary releases GH in discrete bursts, primarily during sleep and fasting periods. The liver and target tissues respond to these pulses for IGF-1 production and anabolic signaling.
Exogenous HGH suppresses the body's natural pulsatile secretion. While it supplies GH, it does so in a continuous, non-pulsatile pattern that doesn't replicate the natural rhythm. Long-term exogenous HGH use is associated with pituitary downregulation — the gland produces less of its own GH because the feedback loop detects sufficient levels.
GH secretagogues (particularly the no-DAC forms like CJC-1295 no DAC + Ipamorelin) preserve and amplify the natural pulsatile pattern. The pituitary retains its normal secretory function; the secretagogue just increases pulse amplitude.
Comparison table
| Property | Exogenous HGH (somatropin) | GH Secretagogues (CJC-1295/Ipa) |
|---|---|---|
| Source of GH | Injected externally | Produced by your own pituitary |
| GH release pattern | Continuous; suppresses natural pulses | Pulsatile; amplifies natural rhythm |
| Effect on pituitary | Downregulates natural production | Stimulates; preserves function |
| IGF-1 elevation | Higher; dose-dependent | Moderate; limited by pituitary capacity |
| Ceiling on effect | Limited by dose (no pituitary ceiling) | Limited by pituitary GH reserve |
| US regulatory status | Schedule III (DESI); Rx required; FDA-approved for specific indications | Not FDA-approved; available via compounding Rx in some states |
| Typical use context | Diagnosed GH deficiency; anti-aging clinics; bodybuilding (illicit) | Research; compounding pharmacy protocols; longevity practices |
Why secretagogues are not a substitute for HGH in GH deficiency
If the pituitary cannot produce adequate GH — as in true GH deficiency from pituitary damage, tumors, or congenital conditions — a secretagogue cannot compensate. It signals a gland that cannot respond adequately. In these cases, exogenous somatropin is the standard of care because it replaces what the pituitary cannot produce.
Secretagogues are appropriate for people with a functioning pituitary who want to increase GH secretion within the pituitary's natural capacity — not for replacing deficient hormone production.
Where BPC-157 fits in this picture
BPC-157 is not a GH secretagogue and is not related to the HGH pathway. It works through nitric oxide signaling, VEGF, and cytoprotective mechanisms — entirely separate from the GH axis. BPC-157 is sometimes stacked with CJC-1295/Ipamorelin in recovery protocols (complementary mechanisms), but it has no direct effect on GH secretion.
See the GH secretagogue mechanism guide for the detailed pharmacology of CJC-1295 and Ipamorelin.
Regulatory note
Exogenous HGH (somatropin) is a Schedule III controlled substance in the US. Non-medical use is illegal regardless of where it's obtained. GH secretagogues occupy a different regulatory category and are available through compounding pharmacies under prescriber order in some states, though their status is evolving. Verify current legal availability with your prescribing provider.
Frequently asked questions
- What is the difference between HGH and CJC-1295/Ipamorelin?
- HGH (somatropin) directly injects exogenous growth hormone, suppresses natural pulsatile secretion, and can produce higher IGF-1 levels than secretagogues. CJC-1295/Ipamorelin stimulates your pituitary to release more of your own GH, preserves pulsatility, and has a ceiling at your pituitary's natural capacity. They are different drug classes with different regulatory statuses.
- Are GH secretagogues safer than HGH?
- They have different risk profiles, not clearly better or worse. Secretagogues preserve natural feedback loops and pulsatility; exogenous HGH suppresses them. Exogenous HGH's long-term effects on pituitary function are more characterized in the literature because it has more clinical trial data. Neither is risk-free. This is a question for your prescribing provider in the context of your specific goals and health status.
- Can GH secretagogues replace HGH if I have growth hormone deficiency?
- No. If you have true GH deficiency from pituitary damage or dysfunction, a secretagogue cannot compensate — it signals a gland that cannot respond adequately. Exogenous somatropin is the standard of care for diagnosed GH deficiency. Secretagogues are for people with functioning pituitaries who want to increase GH within normal capacity.
- Is HGH legal to use without a prescription?
- No. HGH (somatropin) is a Schedule III controlled substance in the US. Use without a valid prescription is illegal regardless of source. GH secretagogues like CJC-1295/Ipamorelin are in a different regulatory category and are available via compounding pharmacy prescriptions in some states — verify current status with your provider.
Sources
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797.
- Ho KKY. GH Deficiency Consensus Workshop participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II. Eur J Endocrinol. 2007;157(6):695-700.
Stop doing this math by hand.
My Pep Calc runs reconstitution, dose tracking, site rotation, and half-life curves for your whole stack — not just one compound.
See the Founders offer →